Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study found that TPA induces apoptosis in pig renal epithelial cells by affecting cell cycle proteins, and activated ras can prevent this process.

Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

An arthritis drug helped a person with severe hair loss regrow their hair.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.